Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
← catalyst calendarSponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
136actual
Sites
42
Countries
Germany, Poland, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-31 | actual | When the study began enrolling |
| Primary completion | 2025-02-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-09 | actual | The whole study's end, after follow-up |
| First posted | 2023-07-07 | actual | When this record first appeared on the registry |
| Results posted | 2026-03-12 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-03-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Urticaria
- Chronic Spontaneous Urticaria
- Chronic Idiopathic Urticaria
- Hives
- Angioedema
- Pruritis
Interventions
- Drug: Povorcitinib
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange From Baseline in the Urticaria Activity Score Over 7 Days (UAS7) at Week 12
measured Baseline; Week 12
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2023-03-07 · 10.1 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-03-20 · 4.3 MB · SAP_001.pdf
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed